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Esophageal Crohn’s Disease Unresponsive
to Glucocorticoids
Tanureet Kochar, MD1, Matthew Krafft, MD2, and Swapna Gayam, MD2
1Department of Internal Medicine, Charleston Area Medical Center, Charleston, WV
2Section of Digestive Diseases, West Virginia University School of Medicine, Morgantown, WV
CASE REPORT
A 24-year-old woman presented with a 1-week history of odynophagia and epigastric abdominal pain. One month before
presentation, the patient was diagnosed with severe ileocolonic Crohn’s disease (CD) and started on glucocorticoids (pred-
nisone 40 mg per oral daily). Esophagogastroduodenoscopy revealed numerous esophageal “punched-out” ulcerations and
erosions throughout the distal and mid esophagus (Figure 1). Biopsy revealed chronic inflammation with lymphoplasmacytic
infiltration of the squamous mucosa (Figure 2). Immunohistochemical stains for cytomegalovirus and herpes simplex virus
were negative. Esophageal CD was highly suspected. Infliximab 5 mg/kg intravenous every 8 weeks and azathioprine 50 mg per
oral daily were started and glucocorticoids were gradually tapered. Upper gastrointestinal symptoms resolved 2 months after
beginning the combination therapy. Repeat esophagogastroduodenoscopy at 6 months revealed esophageal ulcer healing with
residual scarring (Figure 3).
Esophageal CD is a rare entity, with an estimated prevalence of 0.3%–10% in adults with CD.1 The most common presenting
symptoms are odynophagia, dysphagia, heartburn, and chest pain.2 Esophageal CD is rarely the initial disease presentation and
rarely presents concomitantly with intestinal CD. The median interval between the diagnosis of intestinal and esophageal CD is
approximately 1–3 years.1
A retrospective review of 20 patients with esophageal CD by Decker et al found that luminal disease activity occurred most
commonly in the distal esophagus alone (80%), followed by the distal andmid esophagus (15%) and pan esophagus (5%).3 Common
Figure1.Numerouspunched-outulcersanderosions in theesophagus.
Figure 2. Lymphocytes and plasma cells in the submucosa of the
esophagus.
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endoscopic findings include aphthous ulcers, serpiginous
ulcers, nodules, pseudopolyps, skip lesions, and, in severe cases,
strictures and fistulae.1 Esophageal CD can be classified into 3
types: inflammatory, structuring, and fistulizing.6 Chronic in-
flammation is the most common histologic finding, and non-
caseating granulomas are seen in only 7%–9% of cases. A
combination of clinical, endoscopic, and pathologic findings is
required to make the diagnosis.4
There are no treatment guidelines specific for esophageal CD.
Small retrospective studies have shown that esophageal CD
responds to steroids with complete resolutionwithin 2–4 weeks of
therapy.5 In patients who become steroid dependent or respond
inadequately to steroids, immunomodulators have shown to
produce a good clinical response. There have been a few case
reports in which biologics like infliximab and adalimumab were
used to achieve clinical remission in esophagealCD.2 Treatment of
esophageal CD may need to be tailored individually with dilation
for strictures, antibiotics for fistulae, etc., in addition to medical
therapy. There are not many articles highlighting the importance
of combination therapy for esophageal CD, whichmakes our case
unique. In a retrospective observational study, De Felice et al
reported using combination therapy in patients with esophageal
CD.6 They recommended early aggressive combination therapy
in esophageal CD. We conclude that early combination therapy
should be strongly considered in proximal CD.
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Figure 3. Posttreatment endoscopy showing residual scarring after
healing of ulcers.
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